Live feed07:00:00·1681dPRReleasevia QuantisnowOncorus Reports Initial Safety, Tolerability, Immune Activation and Positive Clinical Response Data from its Ongoing Phase 1 Clinical Study of ONCR-177, its Lead Viral Immunotherapy Candidate, at SITC 2021ByQuantisnow·Wall Street's wire, on your screen.ONCR· Oncorus Inc.Health Care
